Global

Investors

CSL Share Price


Price Chart 
View CSL's share price performance over a 12 month period.

Investor Resources
Latest Financial Reports
CSL Profile on ASX website
Dividend Information
Shareholder Information
Computershare's Investor Centre website
Financial Calendar 2013
13 Feb - Results Briefing
14 Aug - Results Briefing
Questions about my Shareholding
Please call CSL's share registry ComputerShare on 1800 646 882 for queries regarding address changes, dividend payments, etc.
Corporate Information
About the CSL Group
Corporate Responsibility
CSL Limited News
CSL Behring News
Investor Contact
Mark Dehring
Mark Dehring
Head of Investor Relations
Phone: +613 9389 2818
mark.dehring@csl.com.au
Subscribe to News Alert
To receive the latest updates about CSL, sign up for our email News Alert.
CSL Limited has over 10,000 staff in more than 20 countries. We produce many life-saving and life-enhancing medicines that enable thousands of people around the world to lead normal healthy lives. Our headquarters is in Australia and we have substantial manufacturing operations in the US, Germany and Switzerland.

CSL is a global specialty biopharmaceutical company that researches, develops, manufactures and markets biotherapies to treat and prevent a range of human medical conditions. We produce safe and effective therapies for patients who rely on them for their quality of life, and sometimes for life itself.

ASX Releases

05/04/2013
CSL Half Year Report 2012-13

28/03/2013
New US$500 million Private Placement
CSL Limited (ASX:CSL) is pleased to announce that on 27 March 2013 it closed a new US$500m Private Placement in the US. More.

08/03/2013
Terms of Appointment of Managing Director and CEO
CSL Limited (ASX:CSL) has previously announced that Mr Paul Perreault will succeed Dr Brian McNamee as Managing Director and Chief Executive Officer of CSL from 1 July 2013. More.

13/02/2013
Half Year Results announcement for 2012/13
CSL Limited (ASX:CSL) today announced a net profit after tax of US$627 million for the six months ended 31 December 2012, up US$123 million or 24% on a reported basis when compared to the prior comparable period (PCP). Earnings per share grew 30%, benefiting from current and past capital management initiatives. More.

13/02/2013
Appointment of Paul Perreault as Executive Director
CSL Limited (ASX:CSL) is pleased to announce the appointment of Mr Paul Perreault to the CSL Limited Board as an Executive Director effective 13 February 2013. More.

13/02/2013
Change to 2013 Dividend Payment Dates
CSL Limited (ASX:CSL) is pleased to announce that, in line with its previous announcement on 17 December 2012 to bring forward the announcement of its Half Year and Full Year Results Announcements by one week, it will also bring forward the payment date of its interim and full year dividends by one week. More.

17/12/2012
2013 Half Year and Full Year Announcement Dates
CSL Limited (ASX:CSL) announced today that it has decided to bring forward the announcement of its Half Year and Full Year Results Announcements by one week. More.

27/11/2012
CSL Lifts Profit Guidance
CSL Limited (ASX:CSL) today announced a revised US Dollar profit outlook for fiscal 2013. The Company now expects net profit after tax to grow by approximately 20% at constant currency1, despite competitive business conditions. More.

05/11/2012
Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option for Reducing Recurrent Heart Attack Risk, Early CSL Studies Show
Infusions of a novel formulation of apolipoprotein A-I (apoA-I) – the main component of high-density lipoprotein (HDL) - rapidly increased the presence of key biomarkers associated with reverse cholesterol transport, a process by which cholesterol is removed from arteries and transported to the liver for clearance, according to data from a Phase 1 study sponsored by CSL Limited. More.

Prior ASX Releases

>> View the ASX Archive